BC Extra | Nov 27, 2019
Company News

Management tracks: Ultragenyx COO to step down next year; plus Agios, MiMedx, Iveric, Ardelyx, Novo Seeds, Axcella, NervGen

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said COO Wladimir Hogenhuis will step down on Jan. 10 due to personal reasons. Cellular metabolism-focused company Agios Pharmaceuticals Inc. (NASDAQ:AGIO) hired Jonathan Biller as chief legal officer,...
BC Extra | Jul 15, 2019
Company News

Management tracks: GSK, Orphazyme, Kymera and more

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined to confirm news reports stating it will appoint Jonathan Symonds as chairman to succeed Philip Hampton, who has served in the role since 2015. The Financial Times and Bloomberg, citing...
BC Week In Review | Feb 1, 2019
Clinical News

Orphazyme finds path forward for Niemann-Pick therapy in subgroup data

Orphazyme A/S (CSE:ORPHA) said arimoclomol significantly reduced disease progression in a pair of predefined subgroups in a Phase II/III trial to treat Niemann-Pick disease type C (NPC). The company plans to meet with FDA and...
BC Extra | Jan 30, 2019
Clinical News

Orphazyme finds path forward for Niemann-Pick therapy in subgroup data

Orphazyme A/S (CSE:ORPHA) gained DKK15 (35%) to DKK58.50 on Wednesday after it said arimoclomol significantly reduced disease progression in a pair of predefined subgroups in a Phase II/III trial to treat Niemann-Pick disease type C...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Oct 19, 2018
Clinical News

Orphazyme seeking path forward for arimoclomol in NPC after Phase II/III miss

Orphazyme A/S (CSE:ORPHA) said arimoclomol missed the primary endpoints in a Phase II/III trial to treat Niemann-Pick disease type C (NPC). The company plans to meet with FDA and EMA to determine next steps for...
BC Extra | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) appointed Margaret Hamburg to its board, effective Jan. 10, 2019. Hamburg is president-elect of the American Association for the Advancement of Science (AAAS), foreign secretary of the National...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BioCentury | Jan 13, 2018
Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
BC Extra | Nov 16, 2017
Financial News

Protein misfolding play Orphazyme prices IPO

Protein misfolding company Orphazyme A/S (CSE:ORPHA TEMP) was unchanged on Thursday after it debuted on NASDAQ Copenhagen, raising DKK 600 million ($94.1 million) in an IPO through the sale of 7.5 million shares at DKK...
Items per page:
1 - 10 of 84